Genmab A/S
GMAB
$24.65
$0.230.94%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 18.74% | 18.57% | 33.98% | 18.63% | 27.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.74% | 18.57% | 33.98% | 18.63% | 27.89% |
| Cost of Revenue | 103.57% | 55.56% | 164.77% | 248.69% | 812.56% |
| Gross Profit | 15.58% | 16.84% | 30.43% | 14.71% | 23.91% |
| SG&A Expenses | 11.63% | 0.80% | 32.38% | 1.49% | 6.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.07% | 8.21% | 37.37% | 14.04% | 31.26% |
| Operating Income | 37.93% | 62.07% | 28.17% | 26.89% | 21.68% |
| Income Before Tax | 37.79% | -2.01% | 254.10% | -35.04% | 24.03% |
| Income Tax Expenses | -16.35% | -14.04% | -179.13% | -19.24% | 98.27% |
| Earnings from Continuing Operations | 65.52% | 1.56% | 441.45% | -39.29% | 4.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.52% | 1.56% | 441.45% | -39.29% | 4.07% |
| EBIT | 37.93% | 62.07% | 28.17% | 26.89% | 21.68% |
| EBITDA | 37.27% | 58.73% | 30.39% | 27.22% | 21.86% |
| EPS Basic | 72.70% | 3.57% | 456.87% | -37.55% | 5.37% |
| Normalized Basic EPS | 31.98% | 13.47% | 332.02% | -37.24% | 26.07% |
| EPS Diluted | 73.16% | 3.93% | 457.77% | -37.42% | 5.63% |
| Normalized Diluted EPS | 32.33% | 13.85% | 332.53% | -37.10% | 26.38% |
| Average Basic Shares Outstanding | -4.16% | -1.93% | -2.77% | -2.77% | -1.23% |
| Average Diluted Shares Outstanding | -4.42% | -2.28% | -2.88% | -2.99% | -1.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |